Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.62 |
| ▸ | CTSB | P07858 | 6/20 | 0.60 |
| ▸ | CTSL | P07711 | 3/20 | 0.60 |
| ▸ | CTSS | P25774 | 4/20 | 0.57 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.56 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986668 | 0.85 | CTSK (0.65) | CTSKCTSBCTSLCTSS | |
| SCHEMBL1375844 | 0.82 | CTSK (0.63) | CTSKCTSBCTSLCTSS | |
| SCHEMBL4987658 | 0.81 | CTSK (0.75) | CTSKCTSBCTSLCTSS | |
| SCHEMBL4988677 | 0.79 | CTSK (0.69) | CTSKCTSBCTSLCTSS | |
| SCHEMBL4988314 | 0.79 | CTSK (0.67) | CTSKCTSBCTSL | |
| SCHEMBL4984773 | 0.79 | CTSK (0.54) | CTSKCTSBCTSLCTSS | |
| SCHEMBL5685359 | 0.79 | CTSK (0.54) | CTSKCTSBCTSLCTSS | |
| SCHEMBL4986728 | 0.78 | CTSK (0.70) | CTSKCTSBCTSLCTSS | |
| SCHEMBL1375902 | 0.78 | CTSK (0.76) | CTSKCTSBCTSLCTSS | |
| SCHEMBL4984939 | 0.78 | CTSK (0.76) | CTSKCTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4690319-B2 | — | — | 2011-06-01 | — | — | JP | claimed |
| US-20070167635-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-07-19 | — | — | US | claimed |
| EP-1644326-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-04-12 | — | — | EP | claimed |
| WO-2005000800-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-01-06 | — | — | WO | claimed |
| US-7405229-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-07-29 | — | — | US | disclosed |
| US-20070167635-A1 | Cathepsin cysteine protease inhibitors | MERCK CANADA INC. (CA) | 2007-07-19 | — | — | US | disclosed |
| EP-1644326-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005000800-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167635-A1 | Cathepsin cysteine protease inhibitors | CTSB, CTSS, CTSK | CTSK 3/4885CTSB 1/4885CTSL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.